Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01731951 · ClinicalTrials.gov registry record · Phase 2
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
A Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT01731951: Completed Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis, sponsored by Geron Corporation.
NCT01731951 is a Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis that has completed, run by Geron Corporation. The registered enrollment target is 80 participants, below the 118-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01731951, a Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
OR:CI/PR/CR per IWG-MRT. CR:Bone marrow (BM):\<5% blasts;≤Grade 1 MF, AND Peripheral blood:Hemoglobin (Hb) ≥100 g/liter (g/L) and \<upper normal limit (UNL);Neutrophil count(NC) ≥1x10\^9/L and \<UNL; Platelet(PLT) count ≥100x10\^9/L and \<UNL;\<2% immature myeloid cells(IMCs), AND Clinical: Resolution of disease symptoms; Spleen and liver not palpable; No evidence of extramedullary hematopoeisis(EMH). PR:All CR criteria plus peripheral blood: Hb≥85 but \<100g/L and \<UNL; NC ≥1x10\^9/L and \<UNL
Conditions Studied
Interventions
- DRUG Imetelstat
Study Locations (1)
Minnesota
- - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2012-10-29 |
| Est. Completion | 2018-05-24 |
| Phase | Phase 2 |
What the finished NCT01731951 record still lists
NCT01731951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 118-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (32% lower).
The record links to 3 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Imetelstat is the first listed.
NCT01731951 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01731951 about?
NCT01731951 is a clinical study titled "Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis". This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01731951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2012-10-29. Estimated completion is 2018-05-24.
What conditions does trial NCT01731951 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Secondary Myelofibrosis, Myeloid Malignancies.
What interventions are being tested in trial NCT01731951?
The interventions under investigation include: Imetelstat (DRUG).
Who is sponsoring clinical trial NCT01731951?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01731951 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01731951's enrollment target sits among peer trials
80 9th of 30 higher than 22 of 30 other Primary Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI